Background: The prognosis of individuals with diabetes mellitus (DM) and chronic renal disease who get regular hemodialysis (HD) is improved by strict glycemic management. Glycated haemoglobin (HbA1c) may not be a useful test for glycemic management in certain patients. Objective: We aimed to assess the efficacy of glycated albumin (GA) versus HbA1c, as a glycemic control indicator, in diabetic patients on HD.  Patients and methods: In between 2016 and 2017; a total of 75 subjects were included in the study. Participants were divided into 3 groups: Group 1; diabetic patients on HD (n=50), Group 2; diabetics with normal renal function (n=10) and Group 3; control group (n=15). Through history and clinical evaluation was performed. GA and HbA1c were done in all groups. Results: diabetic patients on HD had significantly higher GA, while HbA1c was significantly higher in those diabetic patients with normal renal function. GA had 87.1% sensitivity and 72.73% specificity at a cutoff point >31% for prediction of uncontrolled DM in those patients on regular HD while HbA1c had 72% sensitivity and 73% specificity at a cutoff point >6.7%. GA had 67% sensitivity and 85% specificity at a cutoff point >27% for prediction of uncontrolled DM in those patients with normal renal function, while HbA1c had 67% sensitivity and 71% specificity at a cutoff point >7.9%. Conclusion: Glycated albumin could be used as an indicator for glycaemic control in patients on regular HD. Future studies are warranted to confirm such findings.